Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2015 Nov 1;121(21):3844-52.
doi: 10.1002/cncr.29575. Epub 2015 Jul 20.

Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi-institutional study

Koichi Ogura  1   2 , Tomohiro Fujiwara  1   3 , Hideo Yasunaga  4 , Hiroki Matsui  4 , Dae-Geun Jeon  5 , Wan Hyeong Cho  5 , Hiroaki Hiraga  6 , Takeshi Ishii  7 , Tsukasa Yonemoto  7 , Hiroto Kamoda  7 , Toshifumi Ozaki  3 , Eiji Kozawa  8 , Yoshihiro Nishida  8 , Hideo Morioka  9 , Toru Hiruma  10 , Shigeki Kakunaga  11 , Takafumi Ueda  11 , Yusuke Tsuda  2 , Hirotaka Kawano  2 , Akira Kawai  1
Affiliations
Multicenter Study

Development and external validation of nomograms predicting distant metastases and overall survival after neoadjuvant chemotherapy and surgery for patients with nonmetastatic osteosarcoma: A multi-institutional study

Koichi Ogura et al. Cancer. .

Abstract

Background: In this era of individualized cancer treatment, data that could be applied to predicting the survival of patients with osteosarcoma are still limited because of the rarity of the disease and the difficulty in accumulating a sufficient number of patients. Therefore, a multi-institutional collaboration was implemented to develop and externally validate nomograms that would predict metastasis-free survival (MFS) and overall survival (OAS) for patients with nonmetastatic osteosarcoma.

Methods: This study retrospectively examined 1070 patients treated with neoadjuvant chemotherapy and surgery for nonmetastatic osteosarcoma. Data from Japanese patients (n = 557) were used to develop multivariate nomograms based on Cox regression. Six clinical and pathologic variables were built into nomograms estimating the probability of MFS and OAS 3 and 5 years after diagnosis. The model was internally validated for discrimination and calibration with bootstrap resampling and was externally validated with an independent patient cohort from Korea (n = 513).

Results: A patient's age, tumor site, and histologic response were found to have a stronger influence on MFS and OAS in the model than sex, tumor size, or pathologic fracture. The nomograms and calibration plots based on these results well predicted the probability of MFS (concordance index, 0.631) and OAS (concordance index, 0.679). The concordance indices for external validation were 0.682 for MFS and 0.665 for OAS.

Conclusions: The nomograms were externally validated and verified to be useful for the prediction of MFS and OAS and for the assessment of the postoperative prognosis. They can be used for counseling patients and for establishing appropriate surveillance strategies after surgery.

Keywords: external validation; nomogram; osteosarcoma; prognosis; survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan‐Meier curves for (A) metastasis‐free survival and (B) overall survival for all patients.
Figure 2
Figure 2
Nomogram predicting the probability of (A) distant metastasis and (B) overall survival at 3 and 5 years. The patient's value for each variable is plotted on the appropriate scale, and vertical lines are drawn to the line of points to obtain the corresponding scores. All scores should be summed to obtain the total point score. The total point score on the total point line is plotted, and a vertical line is drawn down to the bottom line. The corresponding value shows the predicted probability of distant metastasis or death.
Figure 3
Figure 3
Calibration plot for 3‐year probabilities of (A) distant metastasis and (B) death for external validation.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rosen G, Marcove RC, Huvos AG, et al. Primary osteogenic sarcoma: eight‐year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol. 1983;106(suppl):55‐67. - PubMed
    1. Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987;5:21‐26. - PubMed
    1. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse‐free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314:1600‐1606. - PubMed
    1. Link MP, Goorin AM, Horowitz M, et al. Adjuvant chemotherapy of high‐grade osteosarcoma of the extremity. Updated results of the Multi‐Institutional Osteosarcoma Study. Clin Orthop Relat Res. 1991:8‐14. - PubMed
    1. Bielack SS, Kempf‐Bielack B, Delling G, et al. Prognostic factors in high‐grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776‐790. - PubMed

Publication types

MeSH terms